Recurrent or metastatic head and neck squamous cell carcinoma (RM HNSCC): What about second-line chemotherapy combining cetuximab and platinum-doublet after EXTREME protocol?

Palliative chemotherapy with or without cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck: Indian tertiary care retrospective analysis

“…Of these patients, 55 who received cetuximab had better OS than those receiving only chemotherapy (8.9 months vs 3.5 months, respectively). 31 Overall, cetuximab was well tolerated and the adverse events were consistent with the known safety profile of cetuximab. 26 The incidence of skin rash was approximately 17% in the cetuximab with chemotherapy group, which was similar to that observed in other studies.…”

“…Similar results were observed in other studies where cetuximab was used in the second line of chemotherapy after the first line of chemotherapy failed. 31,32 In the study by Regnier-Gavier et al (2017), 86 patients received a second-line therapy after failure of the first-line therapy. Of these patients, 55 who received cetuximab had better OS than those receiving only chemotherapy (8.9 months vs 3.5 months, respectively).…”

First-line chemotherapy for head and neck squamous cell carcinoma. Optimal strategy

“…[15], важно отметить, что его результаты оказались воспроизводимыми в клинической практике. В ретроспективных рандомизированных исследованиях были получены близкие значения выживаемости без прогрессирования, которая колебалась от 4,3 до 8,8 мес, и ОВ, которая варьировала от 8,8 до 12,6 мес [18][19][20][21][22][23][24][25]. заключение В течение 10 лет режим EXTREME остается наиболее эффективным вариантом лечения, что подтверждено данными как международных, так и наблюдательных исследований.…”